NEUREN PHARMACEUTICALS LTD(NEU.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

NEU.AU NEUREN PHARMACEUTICALS LTD

Not Yet Opened 11-18 16:12:00 AEDT

15.63

-1.08

-6.46%

High16.65	Low15.54	Vol529.45K
Open16.61	D1 Closing16.71	Amplitude6.64%
Mkt Cap2.00B	Tradable Cap1.73B	Total Shares127.82M
T/O8.35M	T/O Rate0.48%	Tradable Shares110.82M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":15.63,"timestamp":1731906720000,"preClose":16.71,"halted":0,"volume":529451,"delay":0,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":110817264,"shares":127815676,"eps":0.894113,"marketStatus":"Not Yet Opened","change":-1.08,"latestTime":"11-18 16:12:00 AEDT","open":16.61,"high":16.65,"low":15.54,"amount":8354631,"amplitude":0.066427,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.894113,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1731970800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":16.71,"openAndCloseTimeList":[[1731884400000,1731906000000]],"volumeRatio":0.7271901438105416,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/NEU.AU/wiki","defaultTab":"wiki","newsList":[{"id":"2483333159","title":"New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483333159","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483333159?lang=en_us&edition=fundamental","pubTime":"2024-11-15 04:00","pubTimestamp":1731614419,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Limited  shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects. Neuren Pharmaceuticals has also found favour with investors, with the stock up a noteworthy 20% to AU$17.30 over the past week. Could this upgrade be enough to drive the stock even higher?Following the latest upgrade, the current consensus, from the six analysts covering Neuren Pharmaceuticals, is for revenues of AU$163m in 2024, which would reflect a considerable 16% reduction in Neuren Pharmaceuticals' sales over the past 12 months. Before the latest update, the analysts were foreseeing AU$123m of revenue in 2024. The consensus has definitely become more optimistic, showing a very substantial lift in revenue forecasts.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/forecasts-heres-analysts-think-future-200019637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NEU","BK7096","BK4109","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2483419353","title":"Here are the best-performing ASX 200 shares since the US election result","url":"https://stock-news.laohu8.com/highlight/detail?id=2483419353","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483419353?lang=en_us&edition=fundamental","pubTime":"2024-11-15 04:00","pubTimestamp":1731614400,"startTime":"0","endTime":"0","summary":"Maybe, maybe not.  Zip has been on a tear all year, up 434% in 2024 alone and up 7.64% since the US election.  Zip has a substantial US business that delivered \"outstanding growth\" in FY24, according to CEO Cynthia Scott.  What are Trump's economic policies?In a recent article, Betashares Senior Investment Strategist Cameron Gleeson provided this handy summary of Trump's economic policies below.  This will provide some clues on how the companies you are invested in might be impacted. Taxes and spending  Cut corporate tax rate from 21% to 15% Increase taxes on buybacks and companies'","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/15/here-are-the-best-performing-asx-200-shares-since-the-us-election-result/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU1720051108.HKD","ZIP.AU","LU1162221912.USD","BK7095","LU1720051017.SGD","LU0267386448.USD","BK4127","BK4588","LU1861559042.SGD","JHX.AU","BK4516","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","MP1.AU","LU0225283273.USD","BK7033","LU1989772840.SGD","AMP.AU","BK7044","LU0006306889.USD","BK7096","SIG.AU","BK7158","LTR.AU","BK4585","XJO.AU","LU0106831901.USD","BK4551","IE00BHPRN162.USD","IE00B19Z3B42.SGD","BK4528","LU0320765646.SGD","BK4106","CTD.AU","LU1074936037.SGD","BK7112","BK7043","NEU.AU","HMC.AU","LU0314104364.USD","JLG.AU","LU0971096721.USD","BK7005","IE00B7SZLL34.SGD","BK7103","BK4554","BK7504","SQ2.AU"],"gpt_icon":1},{"id":"2483484957","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2483484957","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483484957?lang=en_us&edition=fundamental","pubTime":"2024-11-14 13:59","pubTimestamp":1731563994,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) managed to snap the three-day losing streak it had been on this week to push higher today. After falling all week, ASX investors appeared to decide enough was enough t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/14/here-are-the-top-10-asx-200-shares-today-532/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7503","JHX.AU","BK7012","BK7078","BK7044","FLT.AU","BK7070","NUF.AU","CTD.AU","XRO.AU","XJO.AU","RWC.AU","NEU.AU","CWY.AU","WEB.AU","BK7096","BK7047","TAH.AU","BK7020","BK7508","BK7016"],"gpt_icon":1},{"id":"2483689331","title":"Neuren Pharmaceuticals to Launch AU$50 Million Share Buyback; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483689331","media":"MT Newswires Live","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483689331?lang=en_us&edition=fundamental","pubTime":"2024-11-14 10:08","pubTimestamp":1731550114,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  plans to launch a share buyback program of up to 3 million shares worth AU$50 million for up to 12 months, according to a Thursday filing with the Australian bourse.The shares to be acquired represent 2.4% of the company's total shares in issue.The capital deployment comes as the company is poised to receive one-third of the proceeds from the sale of Neuren licensee Acadia Pharmaceuticals' Rare Pediatric Disease Priority Review Voucher for $150 million, the filing said.The pharmaceutical company's shares were up more than 5% in recent Thursday trade.Price : $17.44, Change: $+0.90, Percent Change: +5.44%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0345774631.USD","LU0426417589.USD","LU2238339852.HKD","LU0994945656.USD","NEU.AU","LU1043141123.HKD","LU0426412945.USD","AUD","BK7508","BK4125","BK7096"],"gpt_icon":0},{"id":"2483860830","title":"3 ASX healthcare shares going gangbusters on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2483860830","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483860830?lang=en_us&edition=fundamental","pubTime":"2024-11-14 09:00","pubTimestamp":1731546012,"startTime":"0","endTime":"0","summary":"Three ASX healthcare shares are making their shareholders very happy today, posting gains of 5%, 12% and 19% respectively in morning trade. And this strong performance comes despite some broader healthcare sector headwinds on Thursday, which sees the S&P/ASX 200 Health Care Index  down 0.4% at this same time. So, which three ASX healthcare shares are bucking the trend and flying higher?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/14/3-asx-healthcare-shares-going-gangbusters-on-thursday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IMM.AU","BK7067","BK7508","MSB.AU","BK7501","BK7096","NEU.AU"],"gpt_icon":1},{"id":"2483645668","title":"BUZZ-Australia's Neuren Pharma hits over 3-month high on $32 mln share buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2483645668","media":"reuters","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483645668?lang=en_us&edition=fundamental","pubTime":"2024-11-14 07:47","pubTimestamp":1731541644,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharma hits over 3-month high on $32 mln share buyback ** Shares of Neuren Pharmaceuticals NEU.AX rise as much as 8.4% to A$17.940, their highest since Aug. 5** Stock biggest pct gainer on the benchmark S&P/ASX 200 index .AXJO ** Drug manufacturer announces commencement of on-market share buyback programme of up to A$50 mln ** Says will buy up to 3 mln shares at A$16.540 per share, based on the last close of Wednesday** Stock down 33.8% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL4N3MK2A2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2483940866","title":"BRIEF-Neuren Pharmaceuticals Announces A$50M On-Market Share Buy-Back Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2483940866","media":"reuters","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483940866?lang=en_us&edition=fundamental","pubTime":"2024-11-14 06:14","pubTimestamp":1731536090,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Announces A$50M On-Market Share Buy-Back ProgramNov 14 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:ANNOUNCES A$50M ON-MARKET SHARE BUY-BACK PROGRAMFurther company coverage: NEU.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK340:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2483986698","title":"Neuren Pharmaceuticals Ltd - Announces a$50M on-Market Share Buy-Back Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2483986698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483986698?lang=en_us&edition=fundamental","pubTime":"2024-11-14 06:14","pubTimestamp":1731536056,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK340:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2482371627","title":"Why ANZ, Block, Neuren, and Pilbara Minerals shares are pushing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2482371627","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482371627?lang=en_us&edition=fundamental","pubTime":"2024-11-12 10:29","pubTimestamp":1731378582,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index(ASX: XJO) is on course to record another decline. At the time of writing, the benchmark index is down 0.5% to 8,223.4 points. Four ASX shares that are not lett","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/12/why-anz-block-neuren-and-pilbara-minerals-shares-are-pushing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IE00B19Z3B42.SGD","BK7158","IE00B7SZLL34.SGD","BK4227","LU1861559042.SGD","NEU.AU","BK7135","BK4581","BK7507","LU1861558580.USD","PLS.AU","BK4585","IE00BHPRN162.USD","ANZ.AU","BK4551","SQ2.AU","IE00B19Z3581.USD","IE0002270589.USD","BK7095","BK4106","BK4503","BK7033","MTX","BK4109","BK4528","BK7504","BK4554","XJO.AU","BK7511","BK7096","BK7508","BK4588"],"gpt_icon":0},{"id":"2482761926","title":"Buy this ASX 200 share that is swimming in cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2482761926","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482761926?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:10","pubTimestamp":1731359434,"startTime":"0","endTime":"0","summary":"The market may be nearing a record high, but that doesn't mean there aren't big potential gains to be made. For example, the ASX 200 share in this article, which is swimming in cash, has been tipped rise very strongly from current levels. Which ASX 200 share?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/12/buy-this-asx-200-share-that-is-swimming-in-cash/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["ACAD","LU2065169927.USD","LU2065171402.SGD","WRD","BK7096","LU2065171311.SGD","BK4139","LU2065170008.USD","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2482168827","title":"New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482168827","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482168827?lang=en_us&edition=fundamental","pubTime":"2024-11-12 04:14","pubTimestamp":1731356063,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/new-forecasts-heres-what-analysts-think-the-future-holds-for-260","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU","NEU.AU","BK7508","BK7096","BK4109"],"gpt_icon":1},{"id":"2482462018","title":"Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2482462018","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482462018?lang=en_us&edition=fundamental","pubTime":"2024-11-09 04:00","pubTimestamp":1731096058,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Limited ( ASX:NEU ) shares have had a really impressive month, gaining 26% after a shaky period...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-limiteds-asxneu-shares-climb-26-but-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU","BK4109","BK7096","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2481873167","title":"Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2481873167","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481873167?lang=en_us&edition=fundamental","pubTime":"2024-11-08 10:13","pubTimestamp":1731032010,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is having a great finish to the week. In afternoon trade, the benchmark index is up 0.9% to 8,299.4 points. Four ASX shares that are rising more than most are listed bel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/08/why-imugene-neuren-sigma-and-smartgroup-shares-are-charging-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","IMU.AU","SIG.AU","BK7067","BK7508","SIQ.AU","BK7096","BK7057","NEU.AU","BK7103"],"gpt_icon":0},{"id":"2481603947","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2481603947","media":"MotleyFool","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481603947?lang=en_us&edition=fundamental","pubTime":"2024-11-07 14:10","pubTimestamp":1730959812,"startTime":"0","endTime":"0","summary":"It was a wild session for the S&P/ASX 200 Index (ASX: XJO) this Thursday as investors continued to digest the impact of this week's American elections. After several stints in both positive and negati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/07/here-are-the-top-10-asx-200-shares-today-527/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7157","BK7129","BK7078","BK7096","AAI.AU","BK7055","BK7103","BK7093","SIG.AU","CPU.AU","WOR.AU","BK7508","BK7108","BK7081","BK7034","NEU.AU","BK7503","CCP.AU","TAH.AU","XJO.AU","QBE.AU","BK7033","BSL.AU","JLG.AU"],"gpt_icon":1},{"id":"2481915348","title":"Why Block, GQG, Neuren, and Sigma shares are racing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2481915348","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481915348?lang=en_us&edition=fundamental","pubTime":"2024-11-07 11:01","pubTimestamp":1730948499,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) has failed to follow Wall Street's stunning lead and has dropped into the red. In afternoon trade, the benchmark index is down 0.2% to 8,182.9 points. Four ASX shares t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/07/why-block-gqg-neuren-and-sigma-shares-are-racing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7158","BK4588","BK7508","BK7096","BK4106","IE0002270589.USD","BK4585","LU1861558580.USD","GQG.AU","BK7103","SQ2.AU","BK4554","SIG.AU","BK4503","BK4581","IE00B19Z3581.USD","LU1861559042.SGD","BK4551","BK4227","IE00B7SZLL34.SGD","NEU.AU","BK7062","BK4528","XJO.AU","BK7033","IE00B19Z3B42.SGD","IE00BHPRN162.USD"],"gpt_icon":1},{"id":"2481399725","title":"Neuren Pharmaceuticals Says Daybue Year-to-Date Net Sales Exceeds $250 Million Full-Year Threshold; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481399725","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481399725?lang=en_us&edition=fundamental","pubTime":"2024-11-07 10:25","pubTimestamp":1730946310,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals (ASX:NEU) said net sales of oral Rett syndrome treatment Daybue from January to September exceeded the full-year threshold of $250 million for the company to earn the first sale","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU"],"gpt_icon":1},{"id":"2481996982","title":"BRIEF-Neuren Pharmaceuticals Sees FY24 Income A$216 - 218 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2481996982","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481996982?lang=en_us&edition=fundamental","pubTime":"2024-11-07 09:17","pubTimestamp":1730942250,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Sees FY24 Income A$216 - 218 MlnNov 7 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:SEES FY2024 INCOME A$216 - 218 MILLIONFurther company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nFWN3MD1TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2481088995","title":"BUZZ-Australia's Neuren Pharmaceuticals hits 1-month high on upbeat sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2481088995","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481088995?lang=en_us&edition=fundamental","pubTime":"2024-11-07 09:05","pubTimestamp":1730941548,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharmaceuticals hits 1-month high on upbeat sales** Shares of Neuren Pharmaceuticals NEU.AX rise as much as 8.1% to A$14.350, their highest since Oct. 7** Biopharmaceutical reports Rett syndrome drug Daybue's 9 months net sales exceeded full-year threshold of $250 mln** Co sees full-year income to be in the range of A$216 mln to A$218 mln ** Stock down 43.1% YTD as of 0046 GMT  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4N3ME025:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU"],"gpt_icon":1},{"id":"2481964375","title":"Neuren Pharmaceuticals Ltd - Sees FY2024 Income a$216 - 218 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2481964375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481964375?lang=en_us&edition=fundamental","pubTime":"2024-11-07 07:20","pubTimestamp":1730935218,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nFWN3MD1TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2481620569","title":"Collins Foods And 2 Other ASX Undervalued Small Caps With Insider Buying","url":"https://stock-news.laohu8.com/highlight/detail?id=2481620569","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481620569?lang=en_us&edition=fundamental","pubTime":"2024-11-06 17:06","pubTimestamp":1730883999,"startTime":"0","endTime":"0","summary":"Recent movements in the Australian market have seen the ASX200 rise by 0.83%, with all sectors gaining ground, notably led by IT and Financials. As markets closely monitor ongoing developments such as the US election, investors are increasingly focused on identifying opportunities within small-cap stocks that may offer potential value amidst broader economic shifts. In this context, understanding what constitutes a promising stock—such as solid fundamentals and strategic insider activities—can be crucial for navigating current market conditions effectively.Top 10 Undervalued Small Caps With Insider Buying In Australia. Click here to see the full list of 24 stocks from our Undervalued ASX Small Caps With Insider Buying screener.Operations: The company generates revenue primarily from wholesale computer peripherals, with recent figures reaching A$2.24 billion. Its gross profit margin h","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Lvd_lXQD0CnLIwypMB0Chg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5bcbcb810206bcc5d4f98bf0187f8a6c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Lvd_lXQD0CnLIwypMB0Chg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5bcbcb810206bcc5d4f98bf0187f8a6c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/collins-foods-2-other-asx-090639237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XKO.AU","NEU.AU","XAO.AU","XJO.AU","CKF.AU","BK7508","BK7096","BK7068","BK7137","DDR.AU"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.neurenpharma.com","stockEarnings":[{"period":"1week","weight":-0.0429},{"period":"1month","weight":0.1904},{"period":"3month","weight":0.0202},{"period":"6month","weight":-0.2453},{"period":"1year","weight":0.0647},{"period":"ytd","weight":-0.374}],"compareEarnings":[{"period":"1week","weight":-0.0066},{"period":"1month","weight":-0.0283},{"period":"3month","weight":-0.0172},{"period":"6month","weight":-0.003},{"period":"1year","weight":0.1369},{"period":"ytd","weight":0.1215}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.315789,"avgChangeRate":-0.052499},{"month":2,"riseRate":0.35,"avgChangeRate":-0.043889},{"month":3,"riseRate":0.5,"avgChangeRate":0.37497},{"month":4,"riseRate":0.4,"avgChangeRate":0.012226},{"month":5,"riseRate":0.3,"avgChangeRate":-0.043962},{"month":6,"riseRate":0.65,"avgChangeRate":0.101182},{"month":7,"riseRate":0.3,"avgChangeRate":-0.054407},{"month":8,"riseRate":0.4,"avgChangeRate":0.011765},{"month":9,"riseRate":0.6,"avgChangeRate":0.115169},{"month":10,"riseRate":0.65,"avgChangeRate":0.093961},{"month":11,"riseRate":0.473684,"avgChangeRate":0.038496},{"month":12,"riseRate":0.315789,"avgChangeRate":0.025797}],"exchange":"ASX","name":"NEUREN PHARMACEUTICALS LTD","nameEN":"NEUREN PHARMACEUTICALS LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEUREN PHARMACEUTICALS LTD(NEU.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NEUREN PHARMACEUTICALS LTD(NEU.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NEUREN PHARMACEUTICALS LTD,NEU.AU,NEUREN PHARMACEUTICALS LTD股票,NEUREN PHARMACEUTICALS LTD股票老虎,NEUREN PHARMACEUTICALS LTD股票老虎国际,NEUREN PHARMACEUTICALS LTD行情,NEUREN PHARMACEUTICALS LTD股票行情,NEUREN PHARMACEUTICALS LTD股价,NEUREN PHARMACEUTICALS LTD股市,NEUREN PHARMACEUTICALS LTD股票价格,NEUREN PHARMACEUTICALS LTD股票交易,NEUREN PHARMACEUTICALS LTD股票购买,NEUREN PHARMACEUTICALS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEUREN PHARMACEUTICALS LTD(NEU.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NEUREN PHARMACEUTICALS LTD(NEU.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction